Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Lymphedema.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Lymphedema |
ERG encodes ETS transcription factor ERG (479 aa). Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure Highest expression in Artery Aorta (48.8 TPM) and Artery Tibial (28.1 TPM).
Lymphatic malformation 14 is associated with mutations in the ERG gene on chromosome 21.
The ERG protein participates in ER-to-ERGIC v-SNARES and ERGIC-to-cis-Golgi cargo pathways.
ERG is classified as a druggable target (Clinically Actionable and Druggable Genome categories) with score 4.0.
Genetic testing for ERG is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for lymphatic malformation 14 has been reported in the published literature.
No clinical trials have been registered for lymphatic malformation 14.
90 publications have been identified in PubMed for lymphatic malformation 14. Research spans Case Report / Case Series (36%), Epidemiology / Natural History (18%), and Clinical Trial Publication (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 32 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
16 |
18% |
Clinical study results | 10 | 11% |
Laboratory research | 10 | 11% |
Research summaries | 9 | 10% |
Testing and diagnosis research | 8 | 9% |
New treatment approaches | 4 | 4% |
Other research | 1 | 1% |
Han WT (2026). [PMID: 41834198](https://pubmed.ncbi.nlm.nih.gov/41834198/). *Zhonghua Er Ke Za Zhi*. [Clinical Trial Publication]
Lafranca PPG (2026). [PMID: 41046496](https://pubmed.ncbi.nlm.nih.gov/41046496/). *Spine Deform*. [Epidemiology / Natural History]
Hoyos ME (2026). [PMID: 40403747](https://pubmed.ncbi.nlm.nih.gov/40403747/). *Perfusion*. [Case Report / Case Series]
Singhal KK (2026). [PMID: 41854047](https://pubmed.ncbi.nlm.nih.gov/41854047/). *Pediatr Pulmonol*. [Case Report / Case Series]
Giudice M (2026). [PMID: 42181580](https://pubmed.ncbi.nlm.nih.gov/42181580/). *Front Pediatr*. [Case Report / Case Series]
Yang J (2026). [PMID: 40856600](https://pubmed.ncbi.nlm.nih.gov/40856600/). *Phlebology*. [Gene Therapy / Novel Therapeutics]
Li W (2026). [PMID: 41767703](https://pubmed.ncbi.nlm.nih.gov/41767703/). *Front Surg*. [Epidemiology / Natural History]
Heidary A (2026). [PMID: 42016678](https://pubmed.ncbi.nlm.nih.gov/42016678/). *Clin Case Rep*. [Case Report / Case Series]
Gurung A (2026). [PMID: 41626082](https://pubmed.ncbi.nlm.nih.gov/41626082/). *Clin Case Rep*. [Case Report / Case Series]
Sisk BA (2026). [PMID: 41185141](https://pubmed.ncbi.nlm.nih.gov/41185141/). *Pediatr Blood Cancer*. [Diagnostic / Biomarker]